Cargando…

P1036: VOLUMETRIC SPLENOMEGALY IN PATIENTS WITH POLYCYTHEMIA VERA

Detalles Bibliográficos
Autores principales:	Lee, M.-W., Yeon, S.-H., Ryu, H., Song, I.-C., Lee, H.-J., Yun, H.-J., Kim, S. Y., Lee, J. E., Shin, K. S., Jo, D.-Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429368/ http://dx.doi.org/10.1097/01.HS9.0000847012.33433.27

Ejemplares similares

Volumetric Splenomegaly in Patients With Polycythemia Vera
por: Lee, Myung-Won, et al.
Publicado: (2022)

P1016: POLYCYTHEMIA VERA AND IMMUNE THROMBOGENESIS
por: Cacciola, R., et al.
Publicado: (2022)

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study
por: Accurso, Vincenzo, et al.
Publicado: (2019)

P979: EXOSOMES IN POLYCYTHEMIA VERA: “MINI PLATELETS“ WITH THROMBOGENIC POTENTIAL
por: Abulafia, A., et al.
Publicado: (2022)

Polycythæmia Vera with Tuberculosis Splenomegaly. Report of a Case
por: Guild, A. A., et al.
Publicado: (1950)

P1028: PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA
por: Kuykendall, A., et al.
Publicado: (2022)

Lemierre’s Syndrome in an Elderly Female Patient with Polycythemia Vera: Does Polycythemia Vera Predispose to Lemierre’s Syndrome?
por: Kundal, Sanchit V., et al.
Publicado: (2021)

Anti–IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model
por: Baldauf, Conny K., et al.
Publicado: (2022)

P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS
por: Kuykendall, Andrew, et al.
Publicado: (2023)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023)

P1048: PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA: RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

P1007: PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN JAPANESE PATIENTS WITH POLYCYTHEMIA VERA
por: Kirito, K., et al.
Publicado: (2022)

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
por: Griesshammer, Martin, et al.
Publicado: (2018)

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA
por: Gisslinger, Heinz, et al.
Publicado: (2023)

P1692: UNMET NEEDS IN PATIENTS WITH “LOW RISK” POLYCYTHEMIA VERA (PV): SYMPTOM BURDEN AND QUALITY OF LIFE
por: Nikitina, Tatiana, et al.
Publicado: (2023)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

Hypercalcemia in a Patient with Polycythemia Vera
por: Bae, Eun Hui, et al.
Publicado: (2012)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Bilateral adrenal hemorrhage in polycythemia vera
por: Bhandari, Shruti, et al.
Publicado: (2016)

P1042: COMPARISON OF THE RESPONSE TO ROPEGINTERFERON ALFA-2B IN HYDROXYUREA NAÏVE VERSUS RESISTANCE/INTOLERANCE POLYCYTHEMIA VERA: THE KOREAN SINGLE-ARM, OPEN-LABEL MULTICENTER STUDY
por: Lee, Sung-Eun, et al.
Publicado: (2023)

P1019: A PREDICTION RULE TO GUIDE JAK2 MUTATION TESTING IN PATIENTS WITH SUSPECTED POLYCYTHEMIA VERA: RESULTS FROM THE JAK2 PREDICTION COHORT (JAKPOT) STUDY
por: Chin-Yee, B., et al.
Publicado: (2022)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

A Case of Transition of Polycythemia Vera to Chronic Neutrophilic Leukemia
por: Lee, Seung Soon, et al.
Publicado: (2004)

P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT
por: Mora, B., et al.
Publicado: (2022)

Polycythemia vera presenting with bilateral papilledema
por: Nithyanandam, Suneetha
Publicado: (2009)

Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)

Chorea disclosing a polycythemia vera
por: Liu, Guidong, et al.
Publicado: (2014)

An oncolytic parasite to treat polycythemia vera
por: Rizvi, Syeda Taliya, et al.
Publicado: (2015)

Therapy of polycythemia vera: is it time to change?
por: Passamonti, Francesco, et al.
Publicado: (2017)

Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

When hemolysis masks polycythemia vera
por: Derrieux, Coralie, et al.
Publicado: (2019)

Takotsubo Cardiomyopathy Associated with Polycythemia Vera
por: Basnet, Sijan, et al.
Publicado: (2018)

Is there a gender effect in polycythemia vera?
por: Palandri, Francesca, et al.
Publicado: (2020)

Polycythemia Vera Presenting as Hemorrhagic Stroke
por: Balagopal, Krishnan, et al.
Publicado: (2021)

Polycythemia Vera: Thinking Beyond the Hematocrit
por: Waggoner, Matthew
Publicado: (2023)

A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy
por: Bang, Su-Yeon, et al.
Publicado: (2023)

Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post‐polycythemia vera myelofibrosis
por: Kiso, Shohei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jmggbads58dgn6kpk386b7fu11